VC investments in India at $3.5-bn mark in Q2, 2025: KPMG
KPMG
report.
Fintech remained one of the hottest sectors for investment in India, KPMG Venture Pulse Q2 2025 report said.
Explore courses from Top Institutes in
Select a Course Category
Project Management
Others
Data Science
Operations Management
CXO
PGDM
MBA
Public Policy
Digital Marketing
Technology
Cybersecurity
Data Science
Data Analytics
Design Thinking
MCA
healthcare
Finance
others
Healthcare
Artificial Intelligence
Management
Leadership
Product Management
Degree
Skills you'll gain:
Portfolio Management
Project Planning & Risk Analysis
Strategic Project/Portfolio Selection
Adaptive & Agile Project Management
Duration:
6 Months
IIT Delhi
Certificate Programme in Project Management
Starts on
May 30, 2024
Get Details
Skills you'll gain:
Project Planning & Governance
Agile Software Development Practices
Project Management Tools & Software Techniques
Scrum Framework
Duration:
12 Weeks
Indian School of Business
Certificate Programme in IT Project Management
Starts on
Jun 20, 2024
Get Details
"India's venture capital landscape demonstrated resilience in Q2, 2025, with funding rising despite global uncertainties. Key sectors like fintech, healthtech, and logistics drew strong investor interest, reflecting confidence in India's innovation potential," said Nitish Poddar, Partner and National Leader, Private Equity, KPMG in India.
The performance underscores the country's growing role in shaping the region's startup ecosystem, Poddar added.
A USD 218 million seed round raise by PB Healthcare -- a startup focused on developing a tech-enabled health delivery platform was India's largest VC investment of Q2, 2025.
Live Events
"VC investment in India rose from USD 2.8 billion across 456 deals to USD 3.5 billion across 355 deals quarter-over-quarter," it said.
On a broader canvas, the global venture capital investment slipped to USD 101.05 billion in Q2, 2025 from USD 128.4 billion in Q1, 2025.
The drop notwithstanding, "Q2'25 remained a relatively strong quarter despite ongoing geopolitical conflicts, trade tensions, and macroeconomic uncertainty", as per the report.
The focus remained primarily on large-scale opportunities, especially in the AI and defencetech space, it further said.
Heading into Q3'25, VC investors globally are expected to remain cautious given the continued delay in exits across many sectors, rising geopolitical tensions, and ongoing uncertainties related to tariffs and other global trade policies.
"AI will likely remain the hottest sector of VC investment globally -- particularly as governments continue to introduce large-scale funding programs to attract AI startups and drive ecosystem development and technology sovereignty," according to KPMG.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
9 minutes ago
- News18
Zydus Lifesciences gets tentative nod from USFDA for generic blood cancer drug
New Delhi, Jul 24 (PTI) Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets. The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement. The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added. The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US. PTI RKL DR DR Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
9 minutes ago
- Time of India
Modi, Muizzu & masala: How Maldives went from 'India Out' to strategic warmth
When Prime Minister Narendra Modi lands in the Maldives on Friday for a state visit, he will be greeted not as an outsider, but as the Guest of Honour at the island nation's 60th Independence Day celebrations. Just two years ago, such a scenario would have seemed unlikely. Today, it marks a dramatic shift in bilateral equations, underscoring the quiet resilience of India's strategic diplomacy. Explore courses from Top Institutes in Please select course: Select a Course Category Product Management MBA others Others Technology Cybersecurity Data Science Degree Artificial Intelligence Digital Marketing Healthcare Project Management Public Policy Data Analytics Data Science Finance Management Leadership CXO Design Thinking MCA Operations Management Skills you'll gain: Product Strategy & Competitive Advantage Tactics Product Development Processes & Market Orientations Product Analytics & Data-Driven Decision Making Agile Development, Design Thinking, & Product Leadership Duration: 40 Weeks IIM Kozhikode Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Creating Effective Product Roadmap User Research & Translating it to Product Design Key Metrics via Product Analytics Hand-On Projects Using Cutting Edge Tools Duration: 12 Weeks Indian School of Business ISB Product Management Starts on May 14, 2024 Get Details "Patience has its benefits; it helps if you don't give in to the compulsion and expectation to retaliate against each provocation," a senior source told TOI. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo From 'India Out' to strategic warmth President Mohamed Muizzu swept to power in 2023 on the back of an 'India Out' campaign, signalling what many feared would be a souring of ties. His ministers had publicly criticised India and even targeted PM Modi in a bid to play to nationalist sentiments. The defeat of pro-India President Ibrahim Solih further intensified concerns that Maldives—historically a close ally—was pivoting away from New Delhi. Live Events But instead of reacting to provocation, India chose a policy of 'strategic restraint.' PM Modi was the first world leader to congratulate Muizzu on his election win. And now, just months later, Muizzu is rolling out the red carpet for Modi's visit—a clear sign that political rhetoric has yielded to diplomatic pragmatism. Diplomacy backed by development India's consistent and quiet support to Maldives during economic distress laid the groundwork for this diplomatic turnaround. In 2024, New Delhi extended a $400 million emergency financial package and a Rs 3,000 crore currency swap to stabilize the Maldivian economy. Investments totalling over $450 million are already underway in infrastructure, trade, education, water and sanitation. Muizzu himself acknowledged India's role during his India visit in November, stating: 'India is a key partner in the socio-economic and infrastructure development of the Maldives, and has stood by the Maldives during our times of need.' Among the flagship projects is the Greater Male Connectivity Project , a transformative infrastructure venture linking several islands and boosting economic mobility. Masala diplomacy meets maritime security But this visit isn't just symbolic—it's strategically significant. According to report by ET, Maldives and India are expected to deepen defence and maritime cooperation, particularly in combating drug trafficking across the Arabian Sea and Indian Ocean. President Muizzu has declared the drug menace a national priority, and India is likely to offer greater support through naval collaboration and intelligence sharing. Maldives is already a member of the Colombo Security Conclave (CSC)—a regional initiative led by India to tackle maritime safety, terrorism, cyber threats, and disaster relief. The CSC has evolved into a crucial platform for multilateral cooperation, with Sri Lanka, Mauritius, and Maldives as core members, and Seychelles and Bangladesh as observers. Trade talks, treasury bills, & economic integration As part of the ongoing economic engagement, India and Maldives are in talks for a Free Trade Agreement and a broader investment pact, Foreign Secretary Vikram Misri confirmed earlier this week. He also noted India's sustained subscription to Maldivian treasury bills through the State Bank of India , underlining the financial umbilical cord that links the two nations. Several Memorandums of Understanding (MoUs) are likely to be signed during the prime minister's visit on Friday, covering areas from infrastructure to capacity building. These deals aim to accelerate regional integration and fortify economic stability in the archipelago. A visit rich in symbolism and strategy This will be PM Modi's third state visit to the Maldives—but the first since Muizzu took office. It comes not just as a bilateral gesture but as a regional statement of India's enduring influence, even amid political fluctuations. The timing couldn't be more symbolic—commemorating both 60 years of Maldivian independence and six decades of diplomatic ties with India. By inviting Modi as Guest of Honour, Male has sent a clear signal: despite the turbulence of recent years, India remains a trusted partner in Maldives' journey ahead
News18
11 minutes ago
- News18
Lupin gets USFDA nod for generic diabetes drugs
Agency: PTI New Delhi, Jul 24 (PTI) Drug maker Lupin on Thursday said it has received approval from the US health regulator to market generic medications to treat diabetes. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and glucagon for injection vials, the drug maker said in a statement. Both the products will be manufactured at the company's injectable facility in Nagpur, it added. Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen is bioequivalent to Novo Nordisk Inc's Victoza Injection. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus. As per IQVIA MAT May 2025 data, the injection had an estimated annual sale of USD 458 million in the US. Glucagon for Injection USP, 1 mg/vial, packaged in an emergency kit1, is bioequivalent to Eli Lilly and Company's Glucagon for Injection, 1 mg/vial. It is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. Glucagon for Injection USP, 1 mg/vial, had an estimated annual sale of USD 124 million in the US. 'This is a meaningful enhancement to our portfolio and reaffirms our commitment to expanding access to critical therapies for our patients," Shahin Fesharaki, Chief Scientific Officer, Lupin said. Lupin shares were trading 0.94 per cent up at Rs 1,938.50 apiece on BSE. PTI MSS MSS ANU ANU view comments First Published: July 24, 2025, 14:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
